This video—part 2 of the 5-part Population Health Management (PHM) series—highlights the use of a PHM approach to care in the private practice setting. Dr. Gnanagurudasan Prakasam, MD, discusses the patient experiences that led him to adopt this approach and the social media initiatives that have helped it to flourish. In addition, he offers some insights to those interested in implementing a PHM approach in the private practice setting.
- Fiasp® (insulin aspart injection) 100 U/mL
- Glucagen® (glucagon) for injection 1 mg/mL
- Levemir® (insulin detemir injection) 100 Units/mL
- Novolin® N (isophane insulin human suspension) 100 U/mL
- Novolin® R (insulin human injection) 100 U/mL
- Novolin® 70/30 (70% human insulin isophane suspension and 30% human insulin injection) 100 U/mL
- NovoLog® (insulin aspart injection) 100 units/mL
- NovoLog® Mix 70/30 (70% insulin aspart protamine suspension and 30% insulin aspart injection) 100 units/mL
- Ozempic® (semaglutide) injection 0.5 mg or 1 mg
- Tresiba® (insulin degludec injection) 100 units/mL, 200 units/mL
- Victoza® (liraglutide) injection 1.2 mg or 1.8 mg
- Vagifem® (estradiol vaginal inserts) 10 mcg
- Xultophy® 100/3.6 (insulin degludec and liraglutide injection) 100 units/mL and 3.6 mg/mL
- Rybelsus® (semaglutide) tablets 7 mg or 14 mg
- Saxenda® (liraglutide) injection 3 mg
NovoMedLink
For US Health Care Professionals
